The availability of Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) has dramatically altered the management of heart failure (HF) patients, independently of their ejection fraction and glycemic status. A meta-analysis of 57 studies comparing SGLT2-I monotherapy vs. placebo or active comparator showed reductions in major cardiovascular events, but no impact on atherothrombotic events. In fact, a non-significant increase in the risk for non-fatal stroke was observed. Similar trend observed in multiple trials indicate a SGLT2-i class effect. Sotagliflozin is the first dual SGLT1/2 receptor inhibitor, that was shown to significantly reduce atherothrombotic events compared with placebo in diabetic HF patients, suggesting that dual SGLT1/2 inhibitor may have additional properties vs. SGLT2-i. The hypothesis of this study is that dual SGLT1/2 inhibition by sotagliflozin improves thrombogenic profile (i.e. reduces thrombus formation), which could make it a safer and more effective treatment option for cardiovascular (CV) patients than SGLT2-i. To test the hypothesis, the researchers will compare the antithrombotic activity of sotagliflozin vs. empagliflozin in healthy volunteers using a randomized, cross-over study design, where each participant will receive both study treatments (sotagliflozin and empagliflozin) separated by a washout period. Treatment effects will be assessed by measuring ex vivo thrombus formation using the Badimon Perfusion chamber, platelet aggregation using Multiplate Analyzer, and Thromboelastometry using RoTEM Gamma. Study assessments will be performed before initiating (baseline/pre-treatment) and after completion of each treatment.

Start Date25 Feb 2025

Sponsor / Collaborator

Icahn School of Medicine at Mount Sinai

NCT06147232

/ Not yet recruitingPhase 2IIT

Prevention of CKD Progression in Type 1 Diabetes With Long Term Use of SGLTi Avoiding Kidney hypOxia(PLUTO)

Background: Sodium-glucose-cotransporter (SGLT) inhibition has been observed to reduce risk of cardiovascular events and kidney failure in persons with type 2 diabetes. People with type 1 diabetes also have increased risk of cardiovascular and kidney disease, and may benefit from SGLT-inhibition. The exact mechanism of how SGLT-inhibition benefits the kidneys are yet unknown. Change in renal hypoxia may be a factor.
Objective: The primary aim of this study is to assess the effects of 12 weeks SGLT-1 and 2 inhibition on renal oxygenation in persons with type 1 diabetes and chronic kidney disease.
Further aims are to study if renal oxygen consumption and response to SGLT-inhibition differs between people of African-Caribbean or Northern European decent.
Additionally effects on left ventricular ejection fraction, kidney function and biomarkers in blood and urine will be explored.
Method: 12 weeks treatment with oral sotagliflozin or matching placebo as intervention. Kidney oxygenation and perfusion parameters and left ventricular ejection fraction will be assessed by functional magnetic resonance imaging. Kidney function and biomarkers will be assessed according to local hospital laboratory guidelines.
Design: Randomized, double-blinded, placebo-controlled, cross over intervention study.
Study population: 69 persons with type 1 diabetes and diabetic kidney disease with albuminuria will be included, 39 at Steno Diabetes Center Copenhagen, 30 at King's College London.
Endpoints: Primary end-point: Change from 0 to 12 weeks in dynamic R2*-weighted signal after treatment with sotagliflozin compared to placebo. Secondary endpoints: Change from 0 to 12 weeks with sotagliflozin compared with placebo on renal perfusion, renal artery flow, renal oxygen consumption, renal parenchymal triglyceride fraction, renal fibrosis, left ventricular ejection fraction, urinary albumin-creatinin ratio, ketone bodies, erythropoietin, pro brain natriuretic peptide, and plasma- and urine inflammation- and fibrosis biomarkers as well as difference after 12 weeks treatment in glomerular filtration rate.
Timeframe: Inclusion of patients from february 2024. Last visit september 2025. Presentation spring 2026, publication fall 2026.

Start Date01 Feb 2025

Sponsor / Collaborator

Steno Diabetes Center A/S

[+4]

NCT06435156

/ RecruitingPhase 2IIT

A Phase 2 Double-blind Randomised Controlled Trial Studying the Effect of Sotagliflozin Versus Placebo in Individuals with Heart Failure and Type 1 Diabetes.

People with type 1 diabetes sometimes develop heart failure which can cause symptoms like breathlessness, tiredness or ankle swelling, reduced quality of life and lead to being admitted to hospital or suffering potential fatal consequences. This trial is investigating if a tablet called sotagliflozin, can improve quality of life in people with type 1 diabetes and heart failure. In addition, this trial will also assess the safety and tolerability of sotagliflozin in this population.
In previous trials that included people with type 2 diabetes and heart failure sotagliflozin was shown to improve patients' symptoms of heart failure, quality of life and reduce the chance of people with heart failure being admitted to hospital or dying. However, people with type 1 diabetes and heart failure were not included in these trials meaning that it is not known if these benefits also apply to this population.
This trial aims to recruit 320 people with type 1 diabetes and heart failure symptoms in multiple sites in the United Kingdom (UK). This trial will compare the health and quality of life of participants who take sotagliflozin tablets with participants who take placebo tablets, which is a dummy tablet that looks the same as sotagliflozin. Participants will be randomly allocated to one of two groups (i.e. one taking sotagliflozin and the other the placebo) and both the medical team and participants will not know in which group each participant is until the end of the study. Participants will be in the trial for approximately 6 months and will be given sotagliflozin or placebo tablets to take 1 per day for 4 months. The trial is expected to run for a total of 26 months.

Start Date28 Jan 2025

Sponsor / Collaborator

University Of Dundee

[+2]

100 Clinical Results associated with Sotagliflozin

100 Translational Medicine associated with Sotagliflozin

100 Patents (Medical) associated with Sotagliflozin

327

Literatures (Medical) associated with Sotagliflozin

01 Apr 2025·ESC Heart Failure

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

Article

Author: Kiuchi, Márcio G. ; Templin, Christian ; Meyer, Christian ; Chen, Shaojie ; Ebrahimi, Ramin ; Liu, Shaowen ; Liao, Jia ; Schmidt, Boris ; Acou, Willem‐Jan ; Heukäufer, Matthias ; Derndorfer, Michael ; Chun, Julian K. R. ; Martinek, Martin ; Niel, Johannes ; Ebrahimi, Fahim ; Futyma, Piotr ; Empen, Klaus ; Yin, Yuehui ; Chamling, Bishwas ; Janschel, Sarah ; Dörr, Marcus ; Schratter, Alexandra ; Ling, Zhiyu ; Pürerfellner, Helmut ; Sommer, Philipp ; Di Vece, Davide ; Chen, Yang ; Hummel, Astrid

Abstract:

Aims:

Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.

Methods and Results:

Data was searched in PubMed, Embase, Cochrane Library and clinicaltrials.gov databases up to February 2024. Randomized controlled trials (RCTs) comparing SGLTis with placebo were included. The primary outcomes were individual hard clinical endpoints (Subset A) and QoL (Subset B). For Subset A, 13 RCTs including 90 413 patients were enrolled (age 66 ± 10.1 years, 35.7% female, follow‐up 2.4 ± 0.3 years); as compared with placebo, SGLTis were associated with significantly lower risk of all‐cause mortality [risk ratio (RR): 0.90, 95% confidence interval (CI): 0.86–0.94, P < 0.01], cardiovascular mortality (RR: 0.87, 95% CI: 0.82–0.92, P < 0.01), hospitalization for heart failure (HF) (RR: 0.72, 95% CI: 0.68–0.76, P < 0.01), HF events (RR: 0.72, 95% CI: 0.68–0.75, P < 0.01), hospitalization for any cause (RR: 0.91, 95% CI: 0.88–0.93, P < 0.01) and myocardial infarction (MI) (RR: 0.92, 95% CI: 0.85–0.99, P = 0.03). Notably, the favourable effect of SGLTis on all‐cause mortality was more pronounced in younger (<65 years) patients (RR: 0.86, 95% CI: 0.81–0.92) and in studies with less female (RR: 0.84, 95% CI: 0.79–0.90). The favourable effect of SGLTis on MI was only observed in patients who received sotagliflozin (RR: 0.47, 95% CI: 0.31–0.73). For Subset B, nine RCTs including 2552 HF patients were enrolled (age 67.8 ± 12.4 years, 36.4% female, follow‐up 3.4 ± 1.9 months); SGLTis were associated with significant improvement in QoL as compared with placebo.

Conclusions:

In patients with a broad spectrum of cardiovascular risk factors, SGLTis substantially improve individual hard clinical outcomes and QoL.

01 Apr 2025·ESC Heart Failure

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

Review

Author: Bantounou, Maria Anna ; Philip, Sam ; Black Boada, Daniel ; Kaczmarek, Justyna ; Plascevic, Josip ; Sardellis, Panagiotis ; Awaes‐Mahmood, Ribeya ; Thuemmler, Rosa

Abstract:

Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from inception until 2 June 2023. Randomized controlled trials evaluating sotagliflozin in type 2 diabetes participants and reporting HF events were selected. Major adverse cardiovascular events (MACE) and systolic blood pressure were evaluated. The Cochrane risk of bias tool (RoB 2.0) was used. Pooled mean difference (MD), relative risk (RR), 95% confidence intervals and the number needed to treat (NNT) were estimated (PROSPERO: CRD42023432732). We selected nine studies (n = 15 320 participants: n = 8040 intervention and n = 7280 control). The median follow‐up was 13.4 months (Q1 = 13, Q3 = 21). One study recruited participants with HF at baseline. After a follow‐up of >52 weeks, sotagliflozin significantly reduced the risk of HF [n = 8 studies; RR = 0.66 (0.64, 0.69)], stroke [n = 6 studies; RR = 0.75 (0.58, 0.97)] and MACE [n = 8 studies; RR = 0.73 (0.66, 0.81)]. The NNT was 20 and 26 for HF and MACE, respectively. Sotagliflozin lowered systolic blood pressure [n = 7; MD = −2.38 mmHg (−2.79, −1.97)]. No dose‐dependent effect was identified for HF [200 mg: RR = 0.38 (0.16, 0.89), 400 mg: RR = 0.57 (0.39, 0.85), P‐value = 0.22]. The high risk of bias was a limitation of this review. Sotagliflozin reduced HF and cardiovascular events in type 2 diabetes participants. Research exploring its effects in HF and comparisons with SGLT2 inhibitors is warranted to determine if dual SGLT inhibition surpasses selective inhibition.

01 Feb 2025·DIABETES OBESITY & METABOLISM

Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4

Letter

Author: Cherney, David Z. I. ; Davies, Michael J. ; Carroll, Amy K. ; Girard, Manon ; Sridhar, Vikas S. ; Banks, Phillip

167

News (Medical) associated with Sotagliflozin

03 Mar 2025

·endpts.com

Lexicon plots Phase 3 trial for diabetic pain drug despite mid-stage flop

Lexicon Pharmaceuticals’ non-opioid drug has failed a mid-stage test in a chronic pain indication — but the company says there’s still a path forward and even potential partnership opportunities for the lower dose. The biotech’s AAK1 inhibitor, dubbed pilavapadin, did not meet the primary endpoint of change from baseline in average daily pain score (ADPS) at eight weeks in the Phase 2b PROGRESS trial in moderate to severe diabetic peripheral neuropathic pain (DPNP). The condition develops when high blood sugar levels damage nerves throughout the body, causing pain and numbness. The primary endpoint miss was driven by a “lack of separation” between the 20 mg dose and placebo, according to a Monday release. The 10 mg pilavapadin dose, meanwhile, demonstrated “early and clinically meaningful separation from placebo” in ADPS, which was maintained throughout the trial, Lexicon said. But the trial technically still failed because its primary endpoint was designed to detect a “dose-response signal” that assumed separation from placebo across all treatment cohorts. Detailed results from PROGRESS will be presented at an upcoming medical meeting. Lexicon’s share price $LXRX plummeted around 29% premarket Monday. The Texas biotech still plans to advance the 10 mg dose into Phase 3 based on PROGRESS as well as a previous mid-stage study called RELIEF-DPN-1. The RELIEF-DPN-1 trial tested 10 mg and 20 mg of pilavapadin given after initial loading doses of 100 mg and 200 mg, respectively. By contrast, the PROGRESS trial did not feature a loading dose. In RELIEF-DPN-1, the 10 mg arm met the ADPS primary endpoint at six weeks versus placebo but the 20 mg arm “narrowly missed statistical significance.” In RELIEF-DPN-1, both treatment arms were also negatively impacted by tolerability issues due to the high-loading doses. But in PROGRESS, the 10 mg dose was well tolerated with most side effects being mild or moderate. “The enormous potential of [pilavapadin] has generated significant interest from potential partners, and we intend to accelerate these discussions while we plan for Phase 3 development,” Lexicon CEO Mike Exton said in the Monday release. He added that the neuropathic pain market represents a “multibillion dollar opportunity.” Pilavapadin took center stage for Lexicon in November when the company got rid of its commercial team and switched tack to focus on clinical development. That decision came on the heels of regulatory setbacks for its type 1 diabetes and chronic kidney disease drug sotagliflozin, which faced two rejections from the FDA in the span of five years. In 2022, pilavapadin failed a Phase 2 study in patients with postherpetic neuralgia, a rare side effect of shingles. Editor’s Note: This article was updated to add information about Lexicon’s share price.

Phase 2Phase 3Clinical Result

03 Mar 2025

·www.drugs.com

Sotagliflozin Cuts MACE Rate in Patients With T2DM, CKD, CVD Risk Factors

MONDAY, March 3, 2025 -- For patients with type 2 diabetes , chronic kidney disease, and additional cardiovascular risk factors, the dual sodium-glucose co-transporter (SGLT)-1/2 inhibitor sotagliflozin is associated with a significantly reduced rate of major adverse cardiovascular events (MACE), with independent reductions in myocardial infarction and stroke, according to a study published online Feb. 14 in The Lancet Diabetes & Endocrinology . Rahul Aggarwal, M.D., from Harvard Medical School in Boston, and colleagues conducted a prespecified secondary analysis of the SCORED trial, a double-blind, randomized trial enrolling adult patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors. A total of 10,584 patients from 750 sites in 44 countries were randomly assigned to receive oral sotagliflozin or placebo (5,292 to each group) between Dec. 8, 2017, and Jan. 20, 2020. The researchers found that the rate of total MACE was significantly lower in the sotagliflozin group versus placebo group (4.8 versus 6.3 events per 100 person-years; hazard ratio [HR], 0.77). Among stratified subgroups, there was a consistent effect for sotagliflozin on total MACE, with no evidence of heterogeneity. Compared with placebo, sotagliflozin also significantly reduced the rate of myocardial infarction (1.8 versus 2.7 events per 100 person-years; HR, 0.68) and stroke (1.2 versus 1.8 events per 100 person-years; HR, 0.66). "This ischemic benefit of sotagliflozin on both stroke and myocardial infarction has not been observed in trials of selective SGLT-2 inhibitors, warranting further investigation of SGLT-1 inhibition as a potential mechanism for these effects," the authors write. Several authors disclosed ties to pharmaceutical companies, including Lexicon Pharmaceuticals, which manufactures sotagliflozin and funded the study.

AHAClinical ResultClinical Study

03 Mar 2025

·firstwordpharma.com

Lexicon stumbles on second batch of mixed results for pain drug

Shares in Lexicon Pharmaceuticals crashed over 58% on Monday after its diabetes pain drug candidate pilavapadin (LX9211) missed statistical targets in a mid-stage trial, despite showing a better side-effect profile than in an earlier study. However, the company still plans to advance the drug's lowest dose into final-stage testing.The PROGRESS study tested the oral non-opioid AAK1 inhibitor in 496 adults with diabetic peripheral neuropathic (DPN) pain, evaluating doses of 10 mg, 20 mg, and a 20 mg/10 mg step-down regimen. The treatments led to reductions in average daily pain scores (ADPS) of 1.74, 1.38, and 1.70, respectively, compared to 1.31 for placebo.The study's statistical analysis plan was designed to detect a dose-response signal across all treatment arms from baseline to week eight, but the 20-mg arm's underperformance caused the study to miss statistical significance on its primary endpoint.Removal of loading doseBut unlike the earlier Phase II RELIEF-DPN-1 study, which included problematic 10-fold loading doses on day 1, PROGRESS eliminated the loading dose strategy that had contributed to tolerability problems. Specifically, the loading dose had led to higher rates of dizziness, nausea and headache in RELIEF-DPN-1 that appeared to be related to both dose and treatment duration. The majority of events occurred early in treatment."The tolerability concerns observed in the RELIEF study can now be conclusively ascribed to the loading dose administered on day one," said CEO Mike Exton during Monday's investor call."In both studies [PROGRESS and RELIEF-DPN-1], there is a rapid early separation from placebo with the 10-mg arm that continues throughout the treatment duration," noted Chief Medical Officer Craig Granowitz. "This is particularly notable in PROGRESS, where the placebo response was nearly double that of RELIEF, and yet there is still a rapid and clinically meaningful separation from placebo in progress."Nearly all adverse events in PROGRESS were reported as mild or moderate. Although Granowitz suggested that the "likely explanation" for the lack of separation in the 20-mg arm "is that side effects, such as dizziness, led to a higher dropout rate, and potentially also a lower treatment adherence in those who remained in the study."Scouting for partnersThe setback follows Lexicon's recent struggles to get type 1 diabetes drug Zynquista (sotagliflozin) off the ground, adding pressure on its pipeline. During the investor call, Exton pointed out that pilavapadin's "enormous potential" has generated significant interest from potential partners and that the company is "in active partnership discussions" while preparing for Phase III development.Meanwhile, the company faces competition from Vertex Pharmaceuticals, which recently received FDA approval for the oral NaV1.8 inhibitor Journavx (suzetrigine) in acute pain and is currently enrolling a 1100-patient Phase III study of the drug in DPN pain. The FDA nod marks the first step towards Vertex's goal of making pain medications its next multi-billion-dollar franchise.A January note from Jefferies analysts highlighted that Vertex's separate Phase II DPN pain study of VX-993, a next-generation NaV1.8 inhibitor, has enrolled 192 patients.

Phase 2Phase 3Drug ApprovalClinical Result

100 Deals associated with Sotagliflozin

External Link

KEGG	Wiki	ATC	Drug Bank
D10669	Sotagliflozin	A10BK06	DB12713

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	United States	Lexicon Pharmaceuticals, Inc.	26 May 2023
Diabetes Mellitus, Type 1	European Union	NCI Healthcare LLC	26 Apr 2019
Diabetes Mellitus, Type 1	Iceland	NCI Healthcare LLC	26 Apr 2019
Diabetes Mellitus, Type 1	Liechtenstein	NCI Healthcare LLC	26 Apr 2019
Diabetes Mellitus, Type 1	Norway	NCI Healthcare LLC	26 Apr 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	NDA/BLA	United States	Lexicon Pharmaceuticals, Inc.	21 Jun 2024
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	United States	Lexicon Pharmaceuticals, Inc.	24 Sep 2024
Hypertrophic obstructive cardiomyopathy	Phase 3	United States	Lexicon Pharmaceuticals, Inc.	24 Sep 2024
Diabetes Mellitus, Type 2	Phase 3	United States	Sanofi	01 Nov 2016
Diabetes Mellitus, Type 2	Phase 3	United States	Lexicon Pharmaceuticals, Inc.	01 Nov 2016
Diabetes Mellitus, Type 2	Phase 3	Canada	Sanofi	01 Nov 2016
Diabetes Mellitus, Type 2	Phase 3	Canada	Lexicon Pharmaceuticals, Inc.	01 Nov 2016
Diabetes Mellitus, Type 2	Phase 3	Hungary	Lexicon Pharmaceuticals, Inc.	01 Nov 2016
Diabetes Mellitus, Type 2	Phase 3	Slovakia	Lexicon Pharmaceuticals, Inc.	01 Nov 2016
Hyperglycemia	Phase 3	United States	Sanofi	01 Sep 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03315143 (SCORED, Lancet) Manual	Phase 3	Ischemia	10,584	Sotagliflozin	lilbyscnzx(zjxqtmsscp) = mvcixdzebt ciyqdnpicu (gllftwtljl ) View more	Positive	14 Feb 2025
				Placebo	lilbyscnzx(zjxqtmsscp) = rnwczdsxvm ciyqdnpicu (gllftwtljl ) View more
NCT02531035 \| NCT02384941 \| NCT02421510 (Pubmed) Manual	Not Applicable	Diabetes Mellitus, Type 1 \| Chronic Kidney Diseases	-	Sotagliflozin 200mg (CKD)	ylrgcuuggw(eoxlutiypr) = doxyzqjyyc jmozslxrsi (wffzjwdcte ) View more	Positive	01 Nov 2024
				Sotagliflozin 400mg (CKD)	ylrgcuuggw(eoxlutiypr) = flgdhvdfyt jmozslxrsi (wffzjwdcte ) View more
NCT03285594 (SOTA-INS, GlobeNewswire) Manual	Phase 3	Diabetes Mellitus, Type 2	-	Sotagliflozin 400 mg	wxygrzsmpd(yrgekhjqoz) = xliygoqvqq nujdbdqkxu (nbvayaxnre )	Positive	10 Sep 2024
				Sotagliflozin 200 mg	wxygrzsmpd(yrgekhjqoz) = mhafvcdyip nujdbdqkxu (nbvayaxnre )
NCT03521934 (SOLOIST-WHF, Pubmed \| J Am Coll Cardiol)	Phase 3	Diabetes Mellitus, Type 2 \| Heart Failure	-	Sotagliflozin	mnmpinzsej(mtdwbaubis) = The baseline KCCQ-12 score was low overall (median: 41.7; Q1-Q3: 27.1-58.3) and improved by 4 months in both groups ytagosegif (lzdqyipcps )	Positive	01 Sep 2024
				Placebo
ESC2024	Not Applicable	Diabetes Mellitus	-	Sotagliflozin	wamfmogevp(lylpgzkcnk) = kjhdwposzm ogdaoittnp (vrjjfjotqs ) View more	-	30 Aug 2024
				Placebo	wamfmogevp(lylpgzkcnk) = cugqlluont ogdaoittnp (vrjjfjotqs ) View more
924-P (ADA2024)	Phase 3	Diabetes Mellitus, Type 2 Add-on	570	Sotagliflozin 400 mg	dtmslnyyin(eqhrjlnjnw) = vlbmrvkvmz rllgaqqhac (cpuoacxaat )	Positive	14 Jun 2024
				Sotagliflozin 200 mg	dtmslnyyin(eqhrjlnjnw) = dnlhyseoum rllgaqqhac (cpuoacxaat )
917-P (ADA2024)	Phase 3	Diabetes Mellitus, Type 2	770	Sotagliflozin 400 mg	wqxmjrpmvl(vjerngsoru) = Other adverse events in the SOTA group aligned with expectations associated with SGLTi therapy gvmfiqxnzg (rjvobacshu ) View more	Positive	14 Jun 2024
				Empagliflozin 25 mg
NCT03315143 (SCORED, GlobeNewswire) Manual	Phase 3	Heart Failure	1,932	INPEFA® (sotagliflozin)	jkqwotbpln(povepgtwqt) = oyympebiga qkzzzvfvdj (cmahvqjwbp )	Positive	14 May 2024
SOLOIST-WHF and SCORED (ESC2024)	Not Applicable	obesity \| type 2 diabetes (T2D)	-	Sotagliflozin	ajdckxoyhh(attewjfgbv) = ewuxnxlqoe txlffoeuqg (vdnrzbnney )	Positive	14 May 2024
NCT03315143 (SCORED, ACC2024) Manual	Phase 3	Cardiovascular Diseases \| Diabetes Mellitus, Type 2 \| Chronic Kidney Diseases	10,584	Sotagliflozin	qahlwxfqlh(tsvloytcxj) = fmmjnnclvt ncywfrdump (tacrqdylvh ) View more	Positive	25 Mar 2024
				Placebo	qahlwxfqlh(tsvloytcxj) = rcpvjeqkoc ncywfrdump (tacrqdylvh ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis